Aclaris Therapeutics Inc. (NASDAQ:ACRS) shares traded lower over the last trading session, losing -5.30% on 06/09/21. The shares fell to a low of $16.82 before closing at $17.76. Intraday shares traded counted 1.64 million, which was -160.66% lower than its 30-day average trading volume of 628.44K. ACRS’s previous close was $18.76 while the outstanding shares total 50.34M. The firm has a beta of 0.65. The stock’s Relative Strength Index (RSI) is 30.90, with weekly volatility at 12.25% and ATR at 1.73. The ACRS stock’s 52-week price range has touched low of $1.26 and a $30.38 high.
Investors have identified the Biotechnology company Aclaris Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $933.02 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Aclaris Therapeutics Inc. (ACRS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 134.5 million total, with 14.51 million as their total liabilities.
ACRS were able to record -12.23 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 13.2 million. In cash movements, the company had a total of -12.23 million as operating cash flow.
Potential earnings growth for Aclaris Therapeutics Inc. (ACRS)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/12/2021 quarter of the year, Aclaris Therapeutics Inc. recorded a total of 1.78 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 20.82% coming in sequential stages and their sales for the 08/12/2021 quarter increasing by 11.09%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 1.2 million trying to sell their products during the last quarter, with the result yielding a gross income of 0.57 million. This allows shareholders to hold on to 50.34M with the recently reported earning now reading -0.57 cents per share. This is a figure that compared to analystâ€™s prediction for their 08/12/2021 (-0.57 cents a share).
Having a look at the companyâ€™s valuation, the company is expected to record -1.41 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ACRS sounds very interesting.
Is the stock of ACRS attractive?
In related news, Chief Legal Officer, Ali-Jackson Kamil sold 9,492 shares of the companyâ€™s stock in a transaction that recorded on Jun 03. The sale was performed at an average price of 21.96, for a total value of 208,421. As the sale deal closes, the Chief Scientific Officer, Monahan Joseph now sold 21,790 shares of the companyâ€™s stock, valued at 471,437. Also, President and CEO, Walker Neal sold 33,260 shares of the companyâ€™s stock in a deal that was recorded on Jun 02. The shares were price at an average price of 21.64 per share, with a total market value of 719,735. Following this completion of acquisition, the Chief Legal Officer, Ali-Jackson Kamil now holds 30,119 shares of the companyâ€™s stock, valued at 651,664. In the last 6 months, insiders have changed their ownership in shares of company stock by 3.20%.
5 out of 5 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Aclaris Therapeutics Inc.. 0 analysts has assigned a Sell rating on the ACRS stock. The 12-month mean consensus price target for the companyâ€™s shares has been set at $32.75.